Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8511337 | 1.00 | NTMT1 (0.48) | NTMT1CHRM3CACNA1BCHRM2CHRM4 | |
| SCHEMBL8511560 | 0.90 | CHRM3 (0.48) | NTMT1CHRM3CHRM2CHRM1CHRNA7 | |
| SCHEMBL8511564 | 0.90 | CHRM3 (0.48) | NTMT1CHRM3CHRM2CHRM1CHRNA7 | |
| SCHEMBL8511994 | 0.89 | CHRM3 (0.47) | NTMT1CHRM3CHRM2CHRM1CHRNA7 | |
| SCHEMBL8511562 | 0.89 | NPC1 (0.55) | NTMT1CHRM3CACNA1BCHRNA7BCHE | |
| SCHEMBL8511989 | 0.89 | CHRM3 (0.47) | NTMT1CHRM3CHRM2CHRM1CHRNA7 | |
| SCHEMBL8511559 | 0.89 | NPC1 (0.55) | NTMT1CHRM3CACNA1BCHRNA7BCHE | |
| SCHEMBL2483663 | 0.89 | CHRM3 (0.60) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL2483667 | 0.89 | CHRM3 (0.60) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL8513056 | 0.89 | CHRM3 (0.60) | CHRM3CHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2643295-B1 | GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | CHIESI FARMA SPA (IT) | 2016-04-13 | — | — | EP | disclosed |
| US-8772314-B2 | Glycine derivatives and medicinal compositions thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-07-08 | — | — | US | disclosed |
| EP-2643295-A1 | GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | Chiesi Farmaceutici S.p.A. (IT) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012069275-A1 | GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-05-31 | — | — | WO | disclosed |
| US-20120134934-A1 | GLYCINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134934-A1 | GLYCINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | CHRM3, GLRB, CHRNG | NTMT1 750/4885CHRM3 1/4885CACNA1B 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.